ADMAADMA Biologics, Inc.

$4B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$82M+43.9% YoY

Gross Profit

$39M47.8% margin

Operating Income

$22M26.7% margin

Net Income

$18M21.7% margin

EPS (Diluted)

$0.08

QoQ Revenue Growth

+10.8%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$5M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$351M

Total Liabilities

$197M

Stockholders' Equity

$154M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$82M	$57M	+43.9%
Gross Profit	$39M	$17M	+136.8%
Operating Income	$22M	-$813,000	+2784.0%
Net Income	$18M	-$7M	+362.3%

Revenue Segments

ADMA BioManufacturing Segment

$80M98%

Plasma Collection Centers Segment

$2M2%

Corporate Segment

$36,0000%

Geographic Segments

United States

$78M95%

International

$4M5%

ADMA Q1 2024 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena